#Denmark #Copenhagen #Mabwell #Nectin-4 #9MW2821

Mabwell Unveils Clinical Results of Nectin-4-Targeting ADC 9MW2821

At the European Society for Medical Oncology Gynaecological Cancers Congress 2026, held from June 17 to June 19 in Copenhagen, Denmark, biopharmaceutical company Mabwell presented groundbreaking clinical results for its innovative ADC, 9MW2821, aimed at treating cervical cancer. This event has drawn considerable attention within the oncological community, particularly due to its potential to improve treatment outcomes for patients with recurrent or metastatic cervical cancer.

Promising Safety and Efficacy Results

Two key studies showcased at the congress have confirmed that 9MW2821 demonstrates a manageable safety profile and shows promising therapeutic effects, especially among patients who had previously undergone immunotherapy. The findings indicated that pairing this ADC with a PD-1 inhibitor yields encouraging antitumor activity in patients suffering from advanced cervical cancer.

Prof. Yang Huijuan from Fudan University Shanghai Cancer Center presented detailed insights into these findings, emphasizing the potential benefits of 9MW2821 in clinical practices.

Study Details and Outcomes

The first study was a Phase I/II clinical trial (NCT05216965) focussing on patients with recurrent or metastatic cervical cancer who had not responded to platinum-based chemotherapy. A total of 55 patients were enrolled, with nearly half having also received bevacizumab. Among 53 evaluable patients, the objective response rate (cORR) was recorded at 32.08%, accompanied by an impressive disease control rate (DCR) of 81.13%.

The data revealed a median progression-free survival (mPFS) of 3.9 months and a median overall survival (mOS) of 19.4 months, with 72.7% of patients surviving after one year. Moreover, for patients who had received prior immunotherapy, the outcomes were also promising. The cORR for these patients was reported at 29%, further affirming the potential effectiveness of 9MW2821.

The second study involved combining 9MW2821 with Toripalimab to investigate its safety and efficacy in patients either previously treated or naïve to therapy. With 19 patients enrolled, the results indicated a remarkable objective response rate of 76.9%, of which 100% had disease control.

Future Directions

The innovative nature of 9MW2821 has the potential to redefine treatment paradigms for cervical cancer, possibly establishing it as a first-line therapy for this challenging disease. Mabwell aims to continue its commitment to advancing cancer treatment and has several ongoing Phase III trials targeting different malignancies, including urothelial carcinoma and triple-negative breast cancer.

About Mabwell – the company underlines its mission to deliver creative and effective treatment options that address unmet medical needs in oncology. With their ADC platform, Mabwell is dedicated to exploring life and benefiting health by offering new hope against cancer through pioneering research and clinical developments.

Conclusion

The presentation of 9MW2821's significant findings at the ESMO Congress highlights Mabwell's dedication to innovation in cancer treatment. As clinical trials progress, the potential for 9MW2821 in improving patient outcomes in cervical cancer appears increasingly promising, representing a critical step forward in oncological therapies.